Literature DB >> 27925289

Seroepidemiology of human parechovirus types 1, 3, and 6 in Yamagata, Japan, in 2014.

Shizuka Tanaka1, Yoko Aoki1, Yohei Matoba1, Kazue Yahagi1, Tsutomu Itagaki2, Yoko Matsuzaki3, Katsumi Mizuta1.   

Abstract

To clarify the seroepidemiology of human parechovirus type 1 (HPeV1), 3 and 6, neutralizing antibodies (NT Abs) were measured in 214 serum specimens collected in 2014 in Yamagata, Japan. The seroprevalence against HPeV1 was 100% in all age groups, while that against HPeV3 and HPeV6 was 79.4% and 66.8%, respectively, overall. The geometric mean titers of NT Abs against HPeV1, 3 and 6 were 755.2, 255.0 and 55.9, respectively, overall. Our findings indicate that HPeV1 is the most prevalent HPeV circulating in Yamagata, followed by HPeV3 and HPeV6.
© 2016 The Societies and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  emerging disease; human parechovirus; seroepidemiology

Mesh：

Substances：

Year:  2016        PMID： 27925289     DOI： 10.1111/1348-0421.12456

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN： 0385-5600            Impact factor:   1.955


  9 in total

Review 1.  Human Parechovirus: an Increasingly Recognized Cause of Sepsis-Like Illness in Young Infants.

Authors:  Laudi Olijve; Lance Jennings; Tony Walls
Journal:  Clin Microbiol Rev       Date:  2017-11-15       Impact factor: 26.132

2.  Virome in adult Aedes albopictus captured during different seasons in Guangzhou City, China.

Authors:  Wenqiao He; Yanxia Chen; Xiru Zhang; Mingji Peng; Da Xu; Huan He; Yuhan Gao; Junlin Chen; Jiarui Zhang; Zhiyu Li; Qing Chen
Journal:  Parasit Vectors       Date:  2021-08-18       Impact factor: 3.876

3.  Strain-dependent neutralization reveals antigenic variation of human parechovirus 3.

Authors:  Eveliina Karelehto; Sabine van der Sanden; James A Geraets; Aušra Domanska; Lonneke van der Linden; Dionne Hoogendoorn; Gerrit Koen; Hetty van Eijk; Shabih Shakeel; Tim Beaumont; Menno de Jong; Dasja Pajkrt; Sarah J Butcher; Katja C Wolthers
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

4.  Seroepidemiology of Parechovirus A3 Neutralizing Antibodies, Australia, the Netherlands, and United States.

Authors:  Eveliina Karelehto; Lieke Brouwer; Kimberley Benschop; Jen Kok; Kerri Basile; Brendan McMullan; William Rawlinson; Julian Druce; Suellen Nicholson; Rangaraj Selvarangan; Christopher Harrison; Kamani Lankachandra; Hetty van Eijk; Gerrit Koen; Menno de Jong; Dasja Pajkrt; Katja C Wolthers
Journal:  Emerg Infect Dis       Date:  2019-01       Impact factor: 6.883

Review 5.  Parechovirus A Pathogenesis and the Enigma of Genotype A-3.

Authors:  Adithya Sridhar; Eveliina Karelehto; Lieke Brouwer; Dasja Pajkrt; Katja C Wolthers
Journal:  Viruses       Date:  2019-11-14       Impact factor: 5.048

6.  Two cases of primary human parechovirus pneumonia in adults.

Authors:  Takashi Nishida; Takashi Ishiguro; Kenji Takano; Taisuke Isono; Yoichi Kobayashi; Yoshihiko Shimizu; Noboru Takayanagi
Journal:  Respir Med Case Rep       Date:  2019-10-16

Review 7.  Severe epidemic myalgia with an elevated level of serum interleukin-6 caused by human parechovirus type 3: a case report and brief review of the literature.

Authors:  Kiwamu Nakamura; Kyoichi Saito; Yasuka Hara; Tetsuji Aoyagi; Kadzuhiro Kitakawa; Yoshinobu Abe; Hiromu Takemura; Fumihito Ikeda; Mitsuo Kaku; Keiji Kanemitsu
Journal:  BMC Infect Dis       Date:  2018-08-07       Impact factor: 3.090

8.  Human Parechovirus 1, 3 and 4 Neutralizing Antibodies in Dutch Mothers and Infants and Their Role in Protection Against Disease.

Authors:  Eveliina Karelehto; Joanne G Wildenbeest; Kimberley S M Benschop; Gerrit Koen; Sjoerd Rebers; Saskia Bouma-de Jongh; Brenda M Westerhuis; Menno D de Jong; Dasja Pajkrt; Katja C Wolthers
Journal:  Pediatr Infect Dis J       Date:  2018-12       Impact factor: 2.129

9.  Epidemic Myalgia Associated with Human Parechovirus Type 3 Infection.

Authors:  Moemi Miyazaki; Kenta Hara; Tomofumi Takayoshi; Tetsuya Kawase; Yasushi Nakagawa; Takashi Arai; Takeshi Sugimoto; Katsuhito Nishiyama; Gabriel Gonzalez; Nozomu Hanaoka; Tsuguto Fujimoto; Yoshiro Yasutomo; Koichi Yokono
Journal:  Intern Med       Date:  2019-10-31       Impact factor: 1.271
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.